Avi Pharmaceuticals
Ophthalmic and topical drugs with proprietary gel technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Series A | |
| Total Funding | 000k | ||
Avi Pharmaceuticals (Zhuhai) Co., Ltd. is the Chinese headquarters of the U.S.-based iVIEW Therapeutics, Inc., a clinical-stage ophthalmology therapeutics company. Established in January 2019 in Hengqin New Area, Zhuhai, the company focuses on the development and industrialization of pharmaceuticals for ophthalmology, rhinology, and dermatology. The firm's business model is centered around its core proprietary in-situ gel sustained-release technology platform, which is protected by global intellectual property rights. Avi Pharmaceuticals operates by conducting research and drug registration submissions in both China and the United States, aiming to accelerate project development.
The company was founded by a team of Chinese-American scientists and entrepreneurs, led by founder and CEO Dr. Bo Liang. Dr. Liang holds a bachelor's degree from Peking University, a Ph.D. in organic chemistry from the University of Pennsylvania, and an MBA from NYU's Stern School of Business. His previous success includes the FST-100 eye drop project, which was acquired by Shire for $300 million. The co-founding team includes Dr. John J. Baldwin, who was also a founder of WuXi Apptec and Hua Medicine. The parent company, iVIEW Therapeutics, develops products for conditions such as Acute Infectious Conjunctivitis, Dry Eye Disease (DED), Myopia, and Glaucoma. One of its key products in development is IVW-1001, a novel TRPM8 agonist for treating dry eye disease, which has shown positive results in Phase 1/2 clinical trials.
Financially, Avi Pharmaceuticals has secured significant funding to advance its pipeline. In January 2022, the company raised $25 million in a Series A+ round led by Co-Create Capital. This was followed by another A+ round in January 2025, with lead investment from Pointstone Ventures.
Keywords: ophthalmic therapeutics, in-situ gel technology, sustained-release drug delivery, eye disease treatment, dry eye disease, rhinology, dermatology, clinical-stage pharmaceuticals, TRPM8 agonist, myopia, glaucoma, conjunctivitis, pharmaceutical development, Bo Liang